Comparison of neoantigen-pulsed DC vaccines with the neoantigen-adjuvant vaccine in mouse tumor models demonstrated that, while 4/6 of neoantigen-adjuvant vaccines induced significant neoantigen-specific CD8+ T-cell response, 6/6 of neoantigen-pulsed DC-based vaccines induced strong T-cell response [71]. This evidence concerns the gene CD8A and neoplasm.